Panobinostat (LBH589): Acute Graft Versus Host Disease (aGVHD) Prevention

Inclusion Criteria: * Age ≥ 18 years or older at time of enrollment * Signed informed consent * Hematologic disorder requiring allogeneic hematopoietic cell transplantation * Left ventricular ejection fraction (LVEF) ≥ 45% by multiple uptake gated acquisition (MUGA) scan or echocardiogram * Forced expiratory volume in one second (FEV1), forced vital capacity (FVC), and diffusing lung capacity oxygenation (DLCO) adjusted ≥ 50% of predicted values on pulmonary function tests * Transaminases (AST, ALT) \< 3 times upper limit of normal (ULN) values * Creatinine clearance calculated ≥ 50 mL/min * Karnofsky Performance Status Score ≥ 60%. * Human leukocyte antigen (HLA) matched 8/8 (A, B, C, DRB1) related or unrelated donor Exclusion Criteria: * Active infection not controlled with appropriate antimicrobial therapy * HIV, hepatitis B (HBcAb positive but HBsAg negative with undetectable viral load are eligible), or hepatitis C infection * Sorror's co-morbidity factors with total score \> 4. Important modification to co-morbidity index calculation: DLCO adjusted will not be included in assessment of pulmonary risk, except those patients with DLCO adjusted \< 50% who are excluded from the trial. * Anti-thymocyte globulin (ATG) as part of the conditioning regimen * Cyclophosphamide as part of the conditioning regimen or for GVHD prophylaxis * Pregnancy * Histone deacetylase (HDAC), DAC, HSP90 inhibitors or valproic acid for the treatment of cancer within 30 days * Patients who will need valproic acid for any medical condition during the study or within 5 days prior to first PANO treatment * Impaired cardiac function or clinically significant cardiac diseases, including any one of the following: Any history of ventricular fibrillation or torsade de pointes; Bradycardia defined as heart rate (HR)\< 45 bpm (Patients with pacemakers are eligible if HR ≥ 45 bpm); Screening electrocardiogram (ECG) with a QTcF \> 480 msec; Right bundle branch block + left anterior hemiblock (bifascicular block); Patients with myocardial infarction or unstable angina ≤ 12 months prior to starting study drug; Other clinically significant heart disease (e.g., New York Heart Association (NYHA) class III or IV , uncontrolled hypertension) as per discretion of principal investigator and/or treating physician; Patients using medications that have a relative risk of prolonging the QT interval or inducing torsade de pointes if treatment cannot be discontinued or switched to a different medication prior to starting study drug with the exception of drugs listed on Appendix B of study documents that are required for hematopoietic cell transplantation (HCT) patients.